Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Posted on by ScienceFather

Dr. Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Professor at University of Virginia, United States

Dr. Lian-Wang Guo is a Professor of Biomedical Sciences at the University of Virginia with over 20 years of experience in vascular biology and biochemistry. His research primarily focuses on the role of epigenetic modulators in vascular diseases, particularly neointima-associated restenosis. He has been continuously funded by the NIH since 2012 and has published 48 peer-reviewed papers in the past six years, while also filing six patent applications. Dr. Guo’s innovative work includes developing biomimetic nanoplatforms for targeted drug delivery, which are currently in advanced trials for treating vascular conditions. His research integrates basic science with clinical applications, notably through collaboration with Dr. Craig Kent. Dr. Guo is recognized for his significant contributions to vascular epigenetics and has created a rigorous and inclusive training environment for young researchers. His work holds promise for advancing therapeutic strategies and improving clinical outcomes for vascular diseases.

Professional Profile

Education

Dr. Lian-Wang Guo’s educational background is rooted in biology and advanced plant physiology, providing a strong foundation for his extensive research career. He earned his Bachelor of Science degree in Biology from Xinjiang University in China in 1989, followed by a Master of Science in Plant Physiology from the prestigious Chinese Academy of Sciences in 1992. He continued his studies there, earning a Ph.D. in Plant Physiology and Biochemistry in 1995. Driven by a passion for genetics and biochemistry, Dr. Guo completed a postdoctoral fellowship at The Hebrew University of Jerusalem in 1998, where he broadened his research expertise in molecular biology. His educational journey reflects a commitment to understanding complex biological processes, which he has successfully applied to his pioneering work in vascular biology and epigenetics. Dr. Guo’s solid academic training has been instrumental in his innovative research contributions and leadership in biomedical sciences.

Professional Experience

Dr. Lian-Wang Guo is a tenured Professor of Biomedical Sciences at the University of Virginia, specializing in vascular biology and epigenetics. With over 20 years of research experience, Dr. Guo has developed an expertise in chromatin modulators and their role in vascular diseases, particularly in neointima-associated restenosis. He has been continuously funded by the NIH since 2012, and his prolific contributions include 48 peer-reviewed publications and multiple patents, reflecting his leadership in vascular epigenetics research. His laboratory employs advanced molecular techniques such as ChIPseq, RNAseq, bioinformatics, and innovative nanoplatforms for targeted drug delivery. Dr. Guo has also successfully fostered clinical collaborations, including the development of therapeutic interventions currently undergoing large animal trials, with preparations for human studies. A dedicated mentor, he has cultivated a rigorous training environment for students and fellows, helping them transition into independent research careers. His research has garnered numerous awards and recognition from prominent scientific organizations.

Research Interests

Lian-Wang Guo’s research interests center around the intersection of vascular biology, epigenetics, and targeted drug delivery. As a professor of Biomedical Sciences, his work focuses on understanding the role of chromatin modulators, such as EZH2, DOT1L, and BRD4, in vascular diseases, particularly neointima-associated restenosis. By uncovering how these epigenetic regulators influence disease-specific gene expression, he aims to develop precise therapeutic strategies that mitigate pathological vascular remodeling while preserving normal cellular functions. Dr. Guo is also deeply involved in translational research, advancing the use of biomimetic nanoplatforms for targeted, localized drug delivery. His lab has developed innovative nanotechnologies to deliver therapeutic agents to disease sites, aiming to enhance efficacy and minimize side effects. A key element of his research is the integration of basic science discoveries with clinical applications, as evidenced by his collaborations on vascular disease treatments currently in advanced stages of preclinical testing.

Lian-Wang Guo, Professor of Biomedical Sciences at the University of Virginia, has earned numerous prestigious awards and honors throughout his distinguished career. In 1996, he received the Award of Excellent Sci/Tech Articles from the Chinese Society of Plant Physiology. He has also been recognized with the University of Wisconsin-Madison Eye Research Institute Rapid Response Initiative Award (2008), the Morgridge Institute for Research Award (2014), and the New Investigator Award from the State of Wisconsin Partnership Program (2014). At The Ohio State University, he earned the Accelerator Award for Translation (2017). His editorial contributions include serving as Lead Guest Editor for Genes and Associate Editor for Frontiers in Cardiovascular Medicine. In 2023, he was elected as a Fellow of the American Heart Association (FAHA), and his outstanding research earned him recognition at the 2023 Research Achievement event at the University of Virginia, marking him as a leading figure in vascular biology and biomedical research.

Dr. Lian-Wang Guo’s extensive research contributions, particularly in vascular biology and epigenetics, position him as a leading scholar in biomedical sciences. His innovative work on chromatin modulators, specifically targeting epigenetic players like BRD4, EZH2, and DOT1L, has brought new insights into the treatment of neointimal-associated vascular diseases. Additionally, his development of nano-based, targeted drug delivery systems has shown promising translational potential, bridging the gap between basic science and clinical applications. With over 20 years of experience, numerous high-impact publications, NIH funding, and significant patents, Dr. Guo’s work is both cutting-edge and impactful. His mentorship of the next generation of scientists, as well as his collaborations with leading clinicians, further enhance his academic profile. While his contributions are already significant, a continued focus on clinical translation could maximize the impact of his research. Overall, Dr. Guo exemplifies the qualities of an outstanding researcher deserving of recognition.

 

Publication top noted
  • Article: Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression
    Authors: Li, J., Shen, H., Guo, L.-W.
    Year: 2024
    Citations: 0
  • Article: miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4
    Authors: Xie, X., Shirasu, T., Li, J., Guo, L.-W., Kent, K.C.
    Year: 2023
    Citations: 3
  • Article: Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
    Authors: Shirasu, T., Yodsanit, N., Li, J., Gong, S., Guo, L.-W.
    Year: 2023
    Citations: 1
  • Article: Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms
    Authors: Yodsanit, N., Shirasu, T., Huang, Y., Gong, S., Wang, B.
    Year: 2023
    Citations: 2
  • Article: Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
    Authors: Zhang, M., Li, J., Wang, Q., Miller, C.L., Guo, L.-W.
    Year: 2023
    Citations: 3
  • Article: Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists
    Authors: Li, J., Satyshur, K.A., Guo, L.-W., Ruoho, A.E.
    Year: 2023
    Citations: 3
  • Article: Retinal Photoreceptor Protection in an AMD-Related Mouse Model by Selective Sigma-1 or Sigma-2 Receptor Modulation
    Authors: Mavlyutov, T.A., Li, J., Liu, X., Pattnaik, B., Guo, L.-W.
    Year: 2022
    Citations: 4
  • Erratum: Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction (Cell Death Discovery, (2021), 7, 1, (318), 10.1038/s41420-021-00720-9)
    Authors: Xie, X., Guo, L.-W., Kent, C.K.
    Year: 2022
    Citations: 0
  • Article: Differential Responses to Sigma-1 or Sigma-2 Receptor Ablation in Adiposity, Fat Oxidation, and Sexual Dimorphism
    Authors: Li, J., Félix-Soriano, E., Wright, K.R., Stanford, K.I., Guo, L.-W.
    Year: 2022
    Citations: 5
  • Article: SREBP1 regulates Lgals3 activation in response to cholesterol loading
    Authors: Li, J., Shen, H., Owens, G.K., Guo, L.-W.
    Year: 2022
    Citations: 9

Ehsan Saburi | Molecular Biology | Life Sciences Innovation Award

Posted on by ScienceFather

Dr. Ehsan Saburi | Molecular Biology | Life Sciences Innovation Award

Assistant Professor of Mashhad university of Medical Sciences, Iran.

Dr. Ehsan Saburi is an Assistant Professor at the School of Medicine, Mashhad University of Medical Sciences, specializing in Molecular Medicine. He holds a Ph.D. and has contributed significantly to research in areas such as stem cell therapy, COVID-19, and the molecular mechanisms of various diseases. Dr. Saburi has led numerous research projects, exploring the genetic and molecular aspects of health conditions like COVID-19, cancer, and autoimmune disorders. His work includes the investigation of gene polymorphisms, the therapeutic potential of cell therapy, and the effects of natural compounds on disease progression. Dr. Saburi’s research has been published in high-impact journals, demonstrating his commitment to advancing medical knowledge. His expertise in molecular medicine and his dedication to innovative research make him a strong candidate for the Best Researcher Award.

Profile
Education

Dr. Ehsan Saburi is an accomplished academic with a strong foundation in Molecular Medicine. He earned his Doctor of Philosophy (Ph.D.) in this specialized field, reflecting his deep commitment to advancing medical science. His educational journey is marked by rigorous training and research, equipping him with a profound understanding of molecular mechanisms and their applications in medicine. Dr. Saburi’s academic background is further enriched by his involvement in various research projects at the Mashhad University of Medical Sciences, where he continues to explore the frontiers of medical research. His education has provided him with the skills and knowledge necessary to contribute significantly to the scientific community, particularly in the areas of stem cell research, genetic studies, and the development of innovative medical therapies. Dr. Saburi’s educational achievements underscore his dedication to excellence in both teaching and research, making him a respected figure in his field.

Professional Experience

Dr. Ehsan Saburi is an accomplished Assistant Professor at Mashhad University of Medical Sciences, specializing in Molecular Medicine. With a Ph.D. in the same field, he has played a pivotal role in various research projects, particularly those focusing on the molecular mechanisms of diseases, stem cell therapy, and the impact of genetic polymorphisms on health outcomes. His professional experience is marked by leadership in numerous high-impact studies, including investigations into COVID-19, stem cell differentiation, and the protective effects of natural compounds on organ systems. Dr. Saburi has been instrumental in advancing research in molecular medicine through his extensive work on genetic factors influencing disease severity and innovative therapeutic approaches. His contributions to the academic community are further evidenced by his numerous publications in reputable journals and his active involvement in ongoing research projects aimed at improving health outcomes through molecular and genetic insights.

Research Interest

Dr. Ehsan Saburi’s research interests lie at the intersection of molecular medicine and regenerative medicine, with a particular focus on the therapeutic potential of stem cells and the molecular mechanisms underlying various diseases. His work extensively explores the use of adipose-derived mesenchymal stem cells (AD-hMSCs) in tissue regeneration, particularly in the context of osteogenic and chondrogenic differentiation. Dr. Saburi is also deeply involved in studying the genetic and molecular pathways related to chronic diseases, including cancer and autoimmune disorders. His recent projects have investigated the effects of various bioactive compounds, such as melatonin and curcumin, on mitigating disease symptoms and improving patient outcomes. Additionally, Dr. Saburi’s research includes examining the genetic factors that influence the severity of infectious diseases like COVID-19, aiming to contribute to the development of more effective treatments and vaccines. His multidisciplinary approach positions him at the forefront of translational medicine and therapeutic innovation.

Research Skills

Dr. Ehsan Saburi, an Assistant Professor of Molecular Medicine at Mashhad University of Medical Sciences, demonstrates extensive expertise in advanced molecular and cellular research. His skills encompass a wide range of scientific techniques, including genetic manipulation, stem cell research, and biochemical analysis. Dr. Saburi has led numerous research projects, particularly focusing on the genetic and molecular mechanisms underlying diseases such as cancer, COVID-19, and neurodegenerative disorders. His proficiency in designing and executing complex experiments is evidenced by his successful investigation of various signaling pathways, gene polymorphisms, and therapeutic effects of natural compounds. Additionally, Dr. Saburi is skilled in the use of bioinformatics tools for data analysis and interpretation, contributing to his ability to publish in high-impact journals. His collaborative approach and ability to manage multidisciplinary research teams further highlight his research capabilities, making him a valuable asset in the field of molecular medicine.

Awards and Recognition

Dr. Ehsan Saburi, an accomplished Assistant Professor at Mashhad University of Medical Sciences, has garnered significant recognition for his contributions to molecular medicine. His extensive research on stem cell therapies, COVID-19, and the molecular mechanisms underlying various diseases has earned him numerous accolades. Dr. Saburi’s innovative work on the protective effects of melatonin and curcumin in disease models has been widely acknowledged in the scientific community. He has received several prestigious awards for his groundbreaking research, including the Best Researcher Award from Mashhad University. His publications in high-impact journals and his involvement in pioneering research projects have further solidified his reputation as a leading scientist. Dr. Saburi’s commitment to advancing medical science continues to be recognized through various honors and awards, underscoring his impact on the field and his dedication to improving human health.

Conclusion

Dr. Ehsan Saburi is a highly capable and dedicated researcher with significant contributions to molecular medicine and COVID-19 research. His extensive research activities, leadership in numerous projects, and commitment to advancing medical science make him a strong candidate for the Best Researcher Award. However, to enhance his candidacy further, focusing on the impact of his publications, fostering international collaborations, and pursuing more innovative research avenues would be beneficial.

Publications Top Notes

  1. Title: Advances and challenges of the cell-based therapies among diabetic patients
    Authors: Raoufinia, R., Rahimi, H.R., Saburi, E., Moghbeli, M.
    Journal: Journal of Translational Medicine
    Year: 2024
    Citations: 1
  2. Title: Leveraging stem cells to combat hepatitis: a comprehensive review of recent studies
    Authors: Raoufinia, R., Arabnezhad, A., Keyhanvar, N., Namdar, A.B., Rahimi, H.R.
    Journal: Molecular Biology Reports
    Year: 2024
  3. Title: Hematological changes due to malaria – An update
    Authors: Naser, R.H., Rajaii, T., Farash, B.R.H., Sadabadi, F., Saburi, E.
    Journal: Molecular and Biochemical Parasitology
    Year: 2024
  4. Title: Apoptotic effects of biodentine, calcium-enriched mixture (CEM) cement, ferric sulfate, and mineral trioxide aggregate (MTA) on human mesenchymal stem cells isolated from the human pulp of exfoliated deciduous teeth
    Authors: Nazemi Salman, B., Mohebbi Rad, M., Saburi, E.
    Journal: Minerva Dental and Oral Science
    Year: 2024
  5. Title: Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy
    Authors: Raoufinia, R., Rahimi, H.R., Keyhanvar, N., Foroudi, S., Saburi, E.
    Journal: Stem Cell Reviews and Reports
    Year: 2024
    Citations: 1
  6. Title: Role of microRNAs in tumor progression by regulation of kinesin motor proteins
    Authors: Nasimi Shad, A., Fanoodi, A., Maharati, A., Forouzanfar, F., Moghbeli, M.
    Journal: International Journal of Biological Macromolecules
    Year: 2024
  7. Title: Therapeutic potential of lipid-lowering probiotics on the atherosclerosis development
    Authors: Saadh, M.J., Bazghandi, B., Jamialahmdi, H., Esmaeili, S.-A., Saburi, E.
    Journal: European Journal of Pharmacology
    Year: 2024
  8. Title: Synthesis of bone biocompatible implants using human adipose-derived mesenchymal stem cells (hADMSCs) and PCL/laminin scaffold substrate
    Authors: Zeydari, D., Karimi, E., Saburi, E.
    Journal: Iranian Journal of Basic Medical Sciences
    Year: 2024
    Citations: 2
  9. Title: Genetic landscape of hearing loss in prelingual deaf patients of eastern Iran: Insights from exome sequencing analysis
    Authors: Alerasool, M., Eslahi, A., Vona, B., Niknezhad, H.T., Mojarrad, M.
    Journal: Clinical Genetics
    Year: 2024
  10. Title: Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics
    Authors: Raoufinia, R., Rahimi, H.R., Abbaszadeh, M., Khazaei, M., Avan, A.
    Journal: Current Pharmaceutical Design
    Year: 2024